Urokinase-type plasminogen activator receptor as a predictor of poor outcome in patients with systemic inflammatory response syndrome

doi:10.5847/wjem.j.issn.1920-8642.2013.03.006

Abstract

Abstract:

BACKGROUND: Urokinase-type plasminogen activator (uPA) and urokinase-type plasminogen activator receptor (uPAR) are known as important factors, which mediate a variety of functions in terms of vascular homeostasis, inﬂammation and tissue repair. However, their role in systemic inflammatory response syndrome (SIRS) has been less well studied. This study aimed to test the hypothesis that the abnormalities of fibrinolysis and degradation of extracellular matrix mediated by uPA and uPAR are directly related to the patients with SIRS. We therefore analyzed their role and clinicopathological significance in patients with SIRS.
METHODS: A case-control study was conducted with 85 patients who were divided into two groups according to the diagnostic criteria of SIRS: SIRS group (n=50) and non-SIRS group (n=35). The SIRS group was divided into MODS group (n=26) and non-MODS group (n=24) by their severity, and survival group (n=35) and non-survival group (n=15) by their prognosis. Another 30 healthy adults served as normal controls. uPA and uPAR in plasma were detected by commercial enzyme-linked immunosorbent assay (ELISA) kits.
RESULTS: The plasma level of uPA was lower in the SIRS group than in the non-SIRS group and controls (P<0.001 and P<0.001). It was lower in sepsis patients and the MODS group than in the non-sepsis patients and the non-MODS patients (all P<0.05). However, there was no difference in uPA level between survivors and non-survivors (P>0.05). The plasma level of uPAR increased in the SIRS group compared with the non-SIRS group and controls (P<0.001 and P<0.001). There was a significant elevation of uPAR in sepsis patients, MODS patients and non-survivors as compared with non-sepsis patients, non-MODS patients and survivors respectively (all P<0.05). Plasma uPAR levels were positively correlated with APACHE II score (r=0.575,P<0.001) and SOFA score (r=0.349, P=0.013). AUCs for the prediction of SIRS mortality were 0.67 and 0.51, respectively, for uPA and uPAR.
CONCLUSION: uPAR could be a predictor of poor outcome in patients with SIRS.

Key words: Systemic in?ammatory response syndrome, Multiple organ dysfunction syndrome, Urokinase-type plasminogen activator, Urokinase-type plasminogen activator receptor

Xiao-ling Wu, Ding Long, Li Yu, Jun-hui Yang, Yuan-chao Zhang, Feng Geng. Urokinase-type plasminogen activator receptor as a predictor of poor outcome in patients with systemic inflammatory response syndrome[J]. World Journal of Emergency Medicine, 2013, 4(3): 190-195.

Figures/Tables 8

Table 1

Table 2

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

References 31

1	Hukkanen RR, Liggitt HD, Murnane RD, Frevert CW. Systemic inflammatory response syndrome in nonhuman primates culminating in multiple organ failure, acute lung injury, and disseminated intravascular coagulation. Toxicol Pathol 2009; 37:799-804.
2	Gando S. Microvascular thrombosis and multiple organ dysfunction syndrome. Crit Care Med 2010; 38:S35-42. doi: 10.1097/CCM.0b013e3181c9e31d
3	Pinsky MR. Sepsis and multiple organ failure. Contrib Nephrol 2007; 156:47-63. pmid: 17464115
4	Mondino A, Blasi F. uPA and uPAR in fibrinolysis, immunity and pathology. Trends Immunol 2004; 25:450-455. doi: 10.1016/j.it.2004.06.004 pmid: 15275645
5	Asakura H, Wada H, Okamoto K, Iba T, Uchiyama T, Eguchi Y, et al. Evaluation of haemostatic molecular markers for diagonosis of disseminated intravascular coagulation in patients with infections. Thromb Haemost 2006; 95:282-287.
6	Montuori N, Visconte V, Rossi G, Ragno P. Soluble and cleaved forms of the urokinase-receptor: degradation products or active molecules? Thromb Haemost 2005; 93:192-198. doi: 10.1160/TH04-09-0580 pmid: 15711732
7	Rigolin GM, Tieghi A, Ciccone M, Bragotti LZ, Cavazzini F, Della Porta M, et al. Soluble urokinase-type Plasminngen activator receptor (suPAR) as an independent factor predicting worse prognosis and extra-bone marrow involvement in multiple myeloma patients. Br J Haematol 2003; 120:953-959.
8	Hjertner O, Qvigstad G, Hjorth-Hansen H, Seidel C, Woodliff J, Epstein J, et al. Expression of urokinase plasminogen activator and the urokinase plasminogen activator receptor in myeloma cells. Br J Haematol 2000; 109:815-822. pmid: 10929035
9	Zhou H, Wu X, Lu X, Chen G, Ye X, Huang J. Evaluation of plasma urokinase-type plasminogen activator and urokinase-type plasminogen-activator receptor in patients with acute and chronic hepatitis B. Thromb Res 2009; 123:537-542. doi: 10.1016/j.thromres.2008.06.013 pmid: 18691743
10	Slot O, Brünner N, Locht H, Oxholm P, Stephens RW. Soluble urokinase plasminogen activator receptor in plasma of patients with inflammatory rheumatic disorders: increased concentrations in rheumatoid arthritis. Ann Rheum Dis 1999; 58:488-492.
11	May AE, Schmidt R, Kanse SM, Chavakis T, Stephens RW, Schömig A, et al. Urokinase receptor surface expression regulates monocyte adhesion in acute myocardial infarction. Blood 2002; 100:3611-3617. doi: 10.1182/blood-2002-03-0778 pmid: 12393744
12	Mizukami IF, Faulkner NE, Gyetko MR, Sitrin RG, Todd 3rd RF. Enzyme-linked immunoabsorbent assay detection of a soluble form of urokinase plasminogen activator receptor in vivo. Blood 1995; 86:203-211.
13	Sidenius CF, Sier H, Ullum BK, Pedersen AC, Lepri F, Blasi J, et al. Serum level of soluble urokinase-type plasminogen activator receptor is a strong and independent predictor of survival in human immunodeficiency virus infection, Blood 2000; 96:4091-4095.
14	Ostrowski SR, Katzenstein TL, Pedersen M, Høyer-Hansen G, Gerstoft J, Pedersen BK, et al. Plasma levels of intact and cleaved urokinase receptor decrease in HIV-1 infected patients initiating highly active antiretroviral therapy. Scand J Immunol 2006; 63:478-486. doi: 10.1111/j.1365-3083.2006.001768.x pmid: 16764702
15	Fevang B, Eugen-Olsen J, Yndestad A, Brosstad F, Beiske K, Aukrust P, et al. Enhanced levels of urokinase plasminogen activator and its soluble receptor in common variable immunodeficiency. Clin Immunol 2009; 131:438-446. pmid: 19232508
16	Bone RC, Robert A. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992; 20:864-874. pmid: 1597042
17	Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. 1992. Chest 2009; 136(5 Suppl):e28.
18	Huang LF, Yao YM, Sheng ZY. Novel insights for high mobility group box 1 protein-mediated cellular immune response in sepsis: A systemic review. World J Emerg Med 2012; 3:165-171. pmid: 25215057
19	Yu L, Long D, Wu XL, Yang JH, Yang YC, Feng G. Prognostic significance of urokinase-type plasminogen activator and its receptor in patients with systemic inflammatory response syndrome. World J Emerg Med 2011; 2:185-189. pmid: 25215007
20	García-Fernández N, Montes R, Purroy A, Rocha E. Hemostatic disturbances in patients with systemic inflammatory response syndrome (SIRS) and associated acute renal failure (ARF). Thromb Res 2000; 100:19-25. pmid: 11053612
21	Munzel T, Sinning C, Post F. Pathophysiology diagnosis and prognostic implications of endothelial dysfunction. Ann Med 2008; 40:180-196. doi: 10.1080/07853890701854702 pmid: 18382884
22	Qiu QM, Li ZW, Tang LM, Sun Q, Lu ZQ, Liang H, et al. Expression of high mobility group protein B1 in the lungs of rats with sepsis. World J Emerg Med 2011; 2:302-306. doi: 10.5847/wjem.j.1920-8642.2011.04.011 pmid: 25215028
23	Yu L, Long D, Wu XL, Yang JH, Yang YC, Feng G. Prognostic significance of urokinase-type plasminogen activator and its receptor in patients with systemic inflammatory response syndrome. World J Emerg Med 2011; 2:185-189.
24	Rijneveld AW, Levi M, Florquin S, Speelman P, Carmeliet P, van Der Poll T. Urokinase receptor is necessary for adequate host defense against pneumococcal pneumonia. J Immunol 2002; 168:3507-3511. doi: 10.4049/jimmunol.168.7.3507 pmid: 11907112
25	Blasi F, Sidenius N. The urokinase receptor: focused cell surface proteolysis, cell adhesion and signaling. FEBS Lett 2010; 584:1923-1930. pmid: 20036661
26	Blasi F, Carmeliet P. uPAR: a versatile signalling orchestrator. Nat Rev Mol Cell Biol 2002; 3:932-933. doi: 10.1038/nrm977 pmid: 12461559
27	Blasi F. Proteolysis, cell adhesion, chemotaxis, and invasiveness are regulated by the u-PA-u-PAR-PAI-1 system. Thromb Haemost 1999; 82:298-304.
28	Slot O, Brünner N, Locht H, Oxholm P, Stephens RW. Soluble urokinase plasminogen activator receptor in plasma of patients with inflammatory rheumatic disorders: increased concentrations in rheumatoid arthritis. Ann Rheum Dis 1999; 58:488-492. doi: 10.1136/ard.58.8.488 pmid: 10419867
29	Wittenhagen P, Kronborg G, Weis N, Nielsen H, Obel N, Pedersen SS, et al. The plasma level of soluble urokinase receptor is elevated in patients with Streptococcus pneumoniae bacteriaemia and predicts mortality. Clin Microbiol Infect 2004; 10:409-415. pmid: 15113317
30	Donadello K, Scolletta S, Covajes C, Vincent JL. suPAR as a prognostic biomarker in sepsis. BMC Med 2012; 10:2. doi: 10.1186/1741-7015-10-2 pmid: 22221662
31	Koch A, Voigt S, Kruschinski C, Sanson E, Dückers H, Horn A, et al. Circulating soluble urokinase plasminogen activator receptor is stably elevated during the first week of treatment in the intensive care unit and predicts mortality in critically ill patients. Crit Care 2011; 15:R63.

Variables	Value
Number of patients	50
Average age (yr)	68.2±8.7
Age range (yr)	41-86
Sex (male/female)	26/24
APACHE II score	17.2±5.2
SOFA score	7.1±2.0
Origins of SIRS
Trauma	10
Pneumonia	8
Necrotizing fascitis	3
Cerebral infarction	9
Enterocolitis	4
Necrotizing pancreatitis	8
Pyelonephritis	2
Unstable angina	4
Vasculitis	2

Groups	No. of patients	uPA (ng/mL)	uPAR (ng/mL)
Controls	30	0.817±0.227	1.597±0.680
Non-SIRS	35	0.761±0.269	1.806±0.578
SIRS	50	0.535±0.255^*●	3.923±1.160^*●
Non-sepsis	23	0.662±0.233^*	3.514±0.977^*
Sepsis	27	0.426±0.223^*#	4.272±1.206^*#
Non-MODS	30	0.594±0.269^*	3.609±1.186^*
MODS	20	0.446±0.208^*Δ	4.395±0.967^*Δ
Non-survivors	17	0.552±0.277^*	5.482±1.211^*
Survivors	33	0.526±0.246^*▲	3.635±1.037^*■

[1]	Hai-bo Liu, Min Zhang, Jing-xiao Zhang, Yong-jie Yin. Application of bedside continuous blood purification in patients with multiple organ dysfunction syndromes [J]. World Journal of Emergency Medicine, 2012, 3(1): 40-43.
[2]	Lu-yi Liu, Yong-jian Zhu, Xiao-li Li, Ya-feng Liang, Zuo-peng Liang, Yong-hong Xia. Blood hemoperfusion with resin adsorption combined continuous veno-venous hemofiltration for patients with multiple organ dysfunction syndrome [J]. World Journal of Emergency Medicine, 2012, 3(1): 44-48.
[3]	Li Yu, Ding Long, Xiao-Ling Wu, Jun-hui Yang, Yuan-chao Yang, Geng Feng. Prognostic significance of urokinase-type plasminogen activator and its receptor in patients with systemic inflammatory response syndrome [J]. World Journal of Emergency Medicine, 2011, 2(3): 185-189.